The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial
Open accessAbstract
Importance: Buprenorphine treatment for opioid use disorder may be improved by sustained-release formulations. Objective: To determine whether treatment involving novel weekly and monthly subcutaneous (SC) buprenorphine depot formulations is noninferior to a daily sublingual (SL) combination of buprenorphine hydrochloride and naloxone hydrochloride in the treatment of opioid use disorder. Design, Setting, and Participants: This outpatient, double-blind, double-dummy randomized clinical trial was conducted at 35 sites in the United States from December 29, 2015, through October 19, 2016. Participants were treatment-seeking adults with moderate-to-severe opioid use disorder. Interventions: Randomization to daily SL placebo and weekly (first 12 weeks; phase 1) and monthly (last 12 weeks; phase 2) SC buprenorphine (SC-BPN group) or to daily SL buprenorphine with naloxone (24 weeks) with matched weekly and monthly SC placebo injections (SL-BPN/NX group). Main Outcomes and Measures: Primary end points tested for noninferiority were response rate (10% margin) and the mean proportion of opioid-negative urine samples for 24 weeks (11% margin). Responder status was defined as having no evidence of illicit opioid use for at least 8 of 10 prespecified points during weeks 9 to 24, with 2 of these at week 12 and during month 6 (weeks 21-24). The mean proportion of samples with no evidence of illicit opioid use (weeks 4-24) evaluated by a cumulative distribution function (CDF) was an a priori secondary outcome with planned superiority testing if the response rate demonstrated noninferiority. Results: A total of 428 participants (263 men [61.4%] and 165 women [38.6%]; mean [SD] age, 38.4 [11.0] years) were randomized to the SL-BPN/NX group (n = 215) or the SC-BPN group (n = 213). The response rates were 31 of 215 (14.4%) for the SL-BPN/NX group and 37 of 213 (17.4%) for the SC-BPN group, a 3.0% difference (95% CI, -4.0% to 9.9%; P < .001). The proportion of opioid-negative urine samples was 1099 of 3870 (28.4%) for the SL-BPN/NX group and 1347 of 3834 (35.1%) for the SC-BPN group, a 6.7% difference (95% CI, -0.1% to 13.6%; P < .001). The CDF for the SC-BPN group (26.7%) was statistically superior to the CDF for the SL-BPN/NX group (0; P = .004). Injection site adverse events (none severe) occurred in 48 participants (22.3%) in the SL-BPN/NX group and 40 (18.8%) in the SC-BPN group. Conclusions and Relevance: Compared with SL buprenorphine, depot buprenorphine did not result in an inferior likelihood of being a responder or having urine test results negative for opioids and produced superior results on the CDF of no illicit opioid use. These data suggest that depot buprenorphine is efficacious and may have advantages. Trial Registration: ClinicalTrials.gov Identifier: NCT02651584.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Increases in drug and opioid-involved overdose deaths – United States, 2010-2015
Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm655051e1 · Cited by 2,194
Drug Overdose Deaths in the United States, 1999–2020
Hedegaard, H., Miniño, A., Spencer, M. R., & Warner, M. (2021) · doi:10.15620/cdc:112340 · Cited by 1,283
Higgins (2002) · doi:10.1002/(issn)1097-0258 · Cited by 1,248
The Clinical Opiate Withdrawal Scale (COWS)
Wesson, D. R., & Ling, W. (2003) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2003.10400007 · Cited by 1,120
Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic
Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1402780 · Cited by 1,015
D’Onofrio, G., O’Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A. (2015) · JAMA · doi:10.1001/jama.2015.3474 · Cited by 910
Kampman, K., & Jarvis, M. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000166 · Cited by 678
Self-citationFals-Stewart, W., O'Farrell, T. J., Freitas, T. T., McFarlin, S. K., & Rutigliano, P. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.68.1.134 · Cited by 671
Two New Rating Scales for Opiate Withdrawal
Handelsman, L., Cochrane, K. J., Aronson, M. J., Ness, R., Rubinstein, K. J., & Kanof, P. D. (1987) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952998709001515 · Cited by 599
Treating Drug Abuse and Addiction in the Criminal Justice System: Improving Public Health and Safety
Chandler, R. K., Fletcher, B. W., & Volkow, N. D. (2009) · JAMA · doi:10.1001/jama.2008.976 · Cited by 583
A Controlled Trial of Buprenorphine Treatment for Opioid Dependence
Johnson, R. E. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480200058024 · Cited by 572
Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60358-9 · Cited by 555
Self-citationThe Role of Science in Addressing the Opioid Crisis
Volkow, N. D., & Collins, F. S. (2017) · New England Journal of Medicine · doi:10.1056/nejmsr1706626 · Cited by 555
Treatment of opioid-use disorders
Schuckit, M. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1604339 · Cited by 540
Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540
Suryaprasad, A. G., White, J. Z., Xu, F., Eichler, B.-A., Hamilton, J., Patel, A., Hamdounia, S. B., Church, D. R., Barton, K., Fisher, C., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu643 · Cited by 500
Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12600-1 · Cited by 466
Hser, Y., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., et al. (2014) · Addiction · doi:10.1111/add.12333 · Cited by 455
Ronan, M. V., & Herzig, S. J. (2016) · Health Affairs · doi:10.1377/hlthaff.2015.1424 · Cited by 406
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402
Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence
Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O'Connor, P. G., & Schottenfeld, R. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055255 · Cited by 351
Comparison of buprenorphine and methadone in the treatment of opioid dependence
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.7.1025 · Cited by 305
Buprenorphine suppresses heroin use by heroin addicts
Mello, N. K., & Mendelson, J. H. (1980) · Science · doi:10.1126/science.7352279 · Cited by 298
Lofwall, M. R., & Walsh, S. L. (2014) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000045 · Cited by 248
Self-citationGatekeeping strategies for clinical trials that do not require all primary effects to be significant
Dmitrienko, A., Offen, W. W., & Westfall, P. H. (2003) · Statistics in Medicine · doi:10.1002/sim.1526 · Cited by 227
Hser, Y., Evans, E., Huang, D., Weiss, R., Saxon, A., Carroll, K. M., Woody, G., Liu, D., Wakim, P., Matthews, A. G., et al. (2016) · Addiction · doi:10.1111/add.13238 · Cited by 221
Kakko, J., Grönbladh, L., Svanborg, K. D., von Wachenfeldt, J., Rück, C., Rawlings, B., Nilsson, L.-H., & Heilig, M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.797 · Cited by 197
Effect of Buprenorphine Dose on Treatment Outcome
Fareed, A., Vayalapalli, S., Casarella, J., & Drexler, K. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2011.642758 · Cited by 159
Weiss, R. D., Potter, J. S., Griffin, M. L., Provost, S. E., Fitzmaurice, G. M., McDermott, K. A., Srisarajivakul, E., Dodd, D. R., Dreifuss, J. A., McHugh, R. K., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.02.030 · Cited by 152
Threading the Needle — How to Stop the HIV Outbreak in Rural Indiana
Strathdee, S. A., & Beyrer, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1507252 · Cited by 135
Rosenthal, R. N., Lofwall, M. R., Kim, S., Chen, M. X., Beebe, K. L., Vocci, F. J., & for the PRO-814 Study Group (2016) · JAMA · doi:10.1001/jama.2016.9382 · Cited by 117
Self-citationRosenthal, R. N., Ling, W. W., Casadonte, P. P., Vocci, F. J., Bailey, G. L., Kampman, K. M., Patkar, A. A., Chavoustie, S. E., Blasey, C. M., Sigmon, S. C., et al. (2013) · Addiction · doi:10.1111/add.12315 · Cited by 98
Self-citationWINSTOCK, A. R., Lea, T., & Sheridan, J. L. (2008) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2007.03.002 · Cited by 92
WALSH, S. L., Comer, S. D., Lofwall, M. R., Vince, B. D., Levy‐Cooperman, N., Kelsh, D., Coe, M. A., Jones, J. D., Nuzzo, P. A., Tiberg, F., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1874 · Cited by 87
Self-citationDrug Overdose Deaths in the United States, 1999-2015.
Hedegaard, H. B., Warner, M., & Miniño, A. (2017) · PubMed · Cited by 75
Hser, Y., Huang, D. Y. C., Saxon, A. J., Woody, G., Moskowitz, A. L., Matthews, A. G., & Ling, W. W. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000274 · Cited by 69
Albayaty, M., Linden, M., Olsson, H., Johnsson, M., Strandgården, K., & Tiberg, F. (2017) · Advances in Therapy · doi:10.1007/s12325-016-0472-9 · Cited by 69
Self-citationCiraulo, D. A., HITZEMANN, R. J., Somoza, E. C., Knapp, C. M., Rotrosen, J., Sarid‐Segal, O., Ciraulo, A. M., Greenblatt, D. J., & Chiang, C. N. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005284192 · Cited by 67
Treatment of Opioid-Use Disorders
Winetsky, D., Weinrieb, R. M., & Perrone, J. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1610830 · Cited by 67
Stigma from the Viewpoint of the Patient
Woods, J. S., & Joseph, H. (2015) · Journal of Addictive Diseases · doi:10.1080/10550887.2015.1059714 · Cited by 42
Johnson, B., & Richert, T. (2014) · Journal of Addictive Diseases · doi:10.1080/10550887.2014.975617 · Cited by 40
Amass, L., Pukeleviciene, V., Subata, E., Almeida, A. R., Pieri, M. C., D’Egidio, P. F., Stankova, Z., Costa, A., Smyth, B. P., Sakoman, S., et al. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03577.x · Cited by 28
Toce, M. S., Burns, M. M., & O’Donnell, K. A. (2016) · Clinical Toxicology · doi:10.1080/15563650.2016.1244337 · Cited by 28
Cited by
Strang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F., Marshall, B. D. L., Tyndall, M., & Walsh, S. L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0137-5 · Cited by 639
Self-citationMedication Treatment of Opioid Use Disorder
Bell, J., & Strang, J. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.06.020 · Cited by 328
Improving translation of animal models of addiction and relapse by reverse translation
Venniro, M., Banks, M. L., Heilig, M., Epstein, D. H., & Shaham, Y. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0378-z · Cited by 212
Morgan, J. R., Walley, A. Y., Murphy, S. M., Chatterjee, A., Hadland, S. E., Barocas, J., Linas, B. P., & Assoumou, S. A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108764 · Cited by 67
Treloar, C., Lancaster, K., Gendera, S., Rhodes, T., Shahbazi, J., Byrne, M., Degenhardt, L., & Farrell, M. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103788 · Cited by 52
Metadata
- Authors
- Lofwall, M. R., Walsh, S. L., Nunes, E. V., Bailey, G. L., Sigmon, S. C., Kampman, K. M., Frost, M., Tiberg, F., Linden, M., Sheldon, B., Oosman, S., Peterson, S., Chen, M., & Kim, S.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2018-06-01
- Volume
- 178
- Issue
- 6
- Pages
- 764
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2801225511
- Cited by
- 255
- References
- 47
- FWCI
- 19.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.